Na+/Ca2+ Exchanger type-1 in Arterial Contraction and Salt-induced Hypertension

Na /Ca2 交换器 1 型在动脉收缩和盐诱发高血压中的作用

基本信息

  • 批准号:
    8452207
  • 负责人:
  • 金额:
    $ 35.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-06-01 至 2016-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overall goal of the proposed research is to determine the molecular and physiological mechanisms by which vascular NCX1 (Na+/Ca2+ exchanger type-1) influences arterial blood pressure (BP) normally and in salt- dependent hypertension. Two key determinants of arterial diameter, and hence of arterial BP in vivo, are sympathetic nerve activity (SNA) and myogenic tone (MT). My overall hypothesis is that VSM NCX1 increases both SNA-mediated vasoconstriction and MT, via net Ca2+ influx that increases VSM [Ca2+], and thus regulates BP. Transgenic mice that express altered levels of smooth muscle NCX1 (NCX1smTg/Tg, overexpressors; NCX1sm-/-, knockouts) as well as an exogenous (transgenic) FRET based, Ca2+/calmodulin-myosin light chain kinase (MLCK) activity biosensor molecule will be used. The NCX1 overexpressors will reveal 'gain of function' and knockouts will reveal loss of NCX1 function. Three Specific Aims will be tested: Aim 1: test the hypothesis that vascular NCX1-mediated Ca2+ entry increases cytoplasmic [Ca2+] and activation of MLCK in both SNA-mediated vasoconstriction and in MT in isolated arteries; Aim 2: test the hypothesis that Ca2+ entry via VSM NCX1 also contributes to SNA- and MT-mediated arterial tone in vivo, hence regulates BP; Aim 3: test the hypothesis that salt-dependent hypertension involves further increases in NCX1 activity. The putative cellular mechanism for NCX1 in SNA-mediated contractions is Ca2+ influx via 'reverse mode' NCX1, as a result of local Na+ accumulation after G protein-coupled receptor (GPCR)-induced activation of Na+ permeant transient receptor potential canonical channels, TRPC6. This would increase sarcoplasmic reticulum-dependent Ca2+ waves that activate MLCK. The putative mechanism of NCX1 in MT is Ca2+ influx after stretch activation of Na+ channels (TRPC6 and/or TRPM4). This would increase cytoplasmic [Ca2+]. Confocal '4-D' imaging will be used to observe cytoplasmic Ca2+ waves in isolated pressurized mesenteric small arteries during SNA-mediated contraction. A key technique to be used is intra-vital FRET imaging of exteriorized small arteries of anesthetized living mice to observe [Ca2+], MLCK activation, artery diameter, and carotid artery BP. Salt-dependent hypertension will be induced in biosensor/NCX1 transgenic mice by high salt intake. Blood flow (to determine cardiac output, CO) and telemetric arterial BP will be measured in conscious, freely moving mice. Total peripheral resistance (TPR) will be calculated since BP H CO x TPR. Pharmacological GPCR blockers and a specific NCX blocker (SEA0400) will be administered systemically or locally (to the artery being studied) in the in vivo experiments. The research will elucidate the molecular mechanisms of the established association of BP with vascular NCX1. This knowledge should increase our understanding of salt-dependent hypertension, an increasingly urgent health problem.
描述(由申请人提供):拟定研究的总体目标是确定血管NCX 1(Na+/Ca 2+交换器1型)正常和盐依赖性高血压影响动脉血压(BP)的分子和生理机制。动脉直径以及体内动脉BP的两个关键决定因素是交感神经活性(SNA)和肌源性张力(MT)。我的总体假设是,VSM NCX 1通过增加VSM [Ca 2 +]的净Ca 2+内流增加SNA介导的血管收缩和MT,从而调节BP。将使用表达改变水平的平滑肌NCX 1(NCX 1 smTg/Tg,过表达; NCX 1 sm-/-,敲除)以及基于外源(转基因)FRET的Ca 2 +/钙调蛋白-肌球蛋白轻链激酶(MLCK)活性生物传感器分子的转基因小鼠。NCX 1过表达子将揭示“功能的获得”,敲除将揭示NCX 1功能的丧失。将测试三个特定目的:目的1:测试血管NCX 1介导的Ca 2+内流在SNA介导的血管收缩和MT中增加细胞质[Ca 2 +]和MLCK激活的假设;目的2:测试通过VSM NCX 1的Ca 2+内流也有助于SNA和MT介导的体内动脉张力,从而调节BP的假设;目的3:测试盐依赖性高血压涉及进一步增加NCX 1活性的假设。在SNA介导的收缩中,NCX 1的假定细胞机制是通过“反向模式”NCX 1的Ca 2+内流,这是G蛋白偶联受体(GPCR)诱导的Na+渗透性瞬时受体电位经典通道TRPC 6激活后局部Na+积累的结果。这将增加激活MLCK的肌浆网依赖性Ca 2+波。NCX 1在MT中的假定机制是Na+通道(TRPC 6和/或TRPM 4)牵张激活后的Ca 2+内流。这将增加细胞质[Ca 2 +]。共聚焦“四维”成像将用于观察SNA介导收缩期间离体加压肠系膜小动脉中的细胞质Ca 2+波。使用的关键技术是活体FRET成像的外部小动脉的麻醉活小鼠观察[Ca 2 +],MLCK激活,动脉直径,和颈动脉血压。高盐摄入可诱导生物传感器/NCX 1转基因小鼠产生盐依赖性高血压。将在清醒、自由活动的小鼠中测量血流量(以测定心输出量,CO)和遥测动脉BP。将计算总外周阻力(TPR),因为BP H CO x TPR。在体内实验中,药理学GPCR阻断剂和特异性NCX阻断剂(SEA 0400)将全身或局部(研究动脉)给药。这项研究将阐明BP与血管NCX 1建立联系的分子机制。这些知识应该增加我们对盐依赖性高血压的理解,这是一个日益紧迫的健康问题。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jin Zhang其他文献

Jin Zhang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jin Zhang', 18)}}的其他基金

Integrating multi-omics, imaging, and longitudinal data to predict radiation response in cervical cancer
整合多组学、成像和纵向数据来预测宫颈癌的放射反应
  • 批准号:
    10734702
  • 财政年份:
    2023
  • 资助金额:
    $ 35.7万
  • 项目类别:
HPV genomic structure in cervical cancer radiation response and recurrence detection
HPV基因组结构在宫颈癌放射反应和复发检测中的作用
  • 批准号:
    10634999
  • 财政年份:
    2023
  • 资助金额:
    $ 35.7万
  • 项目类别:
Deep learning in cervical cancer radiogenomics
宫颈癌放射基因组学中的深度学习
  • 批准号:
    10643978
  • 财政年份:
    2022
  • 资助金额:
    $ 35.7万
  • 项目类别:
Deep learning in cervical cancer radiogenomics
宫颈癌放射基因组学中的深度学习
  • 批准号:
    10424854
  • 财政年份:
    2022
  • 资助金额:
    $ 35.7万
  • 项目类别:
HPV alternative splicing in cervical cancer radiation response
HPV选择性剪接在宫颈癌放射反应中的作用
  • 批准号:
    10308435
  • 财政年份:
    2020
  • 资助金额:
    $ 35.7万
  • 项目类别:
HPV alternative splicing in cervical cancer radiation response
HPV选择性剪接在宫颈癌放射反应中的作用
  • 批准号:
    9891761
  • 财政年份:
    2020
  • 资助金额:
    $ 35.7万
  • 项目类别:
HPV alternative splicing in cervical cancer radiation response
HPV选择性剪接在宫颈癌放射反应中的作用
  • 批准号:
    10523104
  • 财政年份:
    2020
  • 资助金额:
    $ 35.7万
  • 项目类别:
FASEB SRC on Protein Kinases and Protein Phosphorylation
FASEB SRC 关于蛋白激酶和蛋白磷酸化
  • 批准号:
    9754337
  • 财政年份:
    2019
  • 资助金额:
    $ 35.7万
  • 项目类别:
Live-cell Activity Architecture in Cancer
癌症中的活细胞活性结构
  • 批准号:
    10673027
  • 财政年份:
    2015
  • 资助金额:
    $ 35.7万
  • 项目类别:
Live-cell Activity Architecture in Cancer
癌症中的活细胞活性结构
  • 批准号:
    9319218
  • 财政年份:
    2015
  • 资助金额:
    $ 35.7万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 35.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 35.7万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 35.7万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 35.7万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 35.7万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 35.7万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 35.7万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 35.7万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 35.7万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 35.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了